pc 버전으로 이동 중 [시장보고서]세계의 IVD 수탁 제조 시장 - 산업 규모, 점유율, 동향, 기회, 예측(2019-2029년)
세계의 IVD 수탁 제조 시장 - 산업 규모, 점유율, 동향, 기회, 예측(2019-2029년)
IVD Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Device Type, By Technology, By Service Type, By Region, and By Competition, 2019-2029F
상품코드 : 1477388
리서치사 : TechSci Research
발행일 : 2024년 05월
페이지 정보 : 영문 182 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,900 ₩ 6,847,000
Unprintable PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.
US $ 5,900 ₩ 8,244,000
PDF and Excel (Multi-User License) help
PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.
US $ 8,900 ₩ 12,436,000
PDF and Excel (Custom Research License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

IVD 수탁 제조(체외진단 수탁 제조, IVD Contract Manufacturing) 시장 규모는 2023년에 154억 7,000만 달러에 이르고, 예측 기간은 2029년까지 CAGR 11.61%로 눈부신 성장을 이룰 것입니다.

시장 개요
예측 기간 2025-2029년
2023년 시장 규모 154억 7,000만 달러
2029년 시장 규모 297억 9,000만 달러
CAGR 2024-2029년 11.61%
급성장 부문 면역 측정
최대 시장 북미

IVD(In Vitro Diagnostics) 수탁 제조란 체외 진단용 의약품 및 서비스에 관한 제조 공정을 제3자의 전문 제조업체에 아웃소싱하는 것입니다. 체외진단제는 인체외의 혈액, 소변, 조직, 기타 체액 등 생물학적 샘플을 분석하고, 질병의 진단, 치료 반응의 모니터링, 건강 상태 전반의 평가를 실시합니다. 수탁 제조업체는 체외 진단용 의약품 개발자, 진단 회사 및 의료 기관과 협력하여 새로운 진단 분석, 검사 키트, 장비 및 소프트웨어 솔루션을 개발합니다. 여기에는 제품 사양 설계, 시약 준비, 구성 요소 선택, 진단 장비 시작 등이 포함됩니다. 수탁 제조업체는 확립된 품질 기준, 규제 요건 및 업계 모범 사례에 따라 체외 진단용 의약품을 제조할 책임이 있습니다. 여기에는 원재료 조달, 부품 제조, 완제품 조립, 품질 관리 시험 실시, 유통을 위한 제품 포장 등이 포함됩니다. 수탁 제조업체는 체외 진단용 의약품의 안전성, 효능 및 신뢰성을 보장하기 위해 견고한 품질 관리 시스템과 규정 준수 프로세스를 도입했습니다. 여기에는 ISO 13485와 같은 국제 품질 표준, FDA 규제, CE 마킹 요구 사항 및 기타 의료기기 및 진단 약물을 관리하는 지역의 규제 프레임워크 준수가 포함됩니다.

분자진단, 면역분석, 포인트 오브 케어 검사, 자동화와 같은 진단 기술의 지속적인 발전은 기술 혁신과 새로운 진단 제품의 개발을 촉진합니다. 체외진단용 의약품 수탁제조업자는 이러한 진보를 활용하여 최첨단 진단기기와 컴포넌트를 개발·제조합니다. 헬스케어 제공업체와 진단약 기업은 업무의 합리화, 비용 절감, 전문적인 전문지식에의 액세스를 목적으로 제조 공정을 전문의 수탁제조업자에게 위탁하는 경우가 늘고 있습니다. 아웃소싱을 통해 기업은 수탁 제조업체의 제조 능력을 활용하면서 R&D, 마케팅 등 핵심 역량에 집중할 수 있습니다. 개인화된 의료 및 정밀 진단이 중요해지며, 개별 환자의 필요에 맞게 맞춤형 진단제가 필요합니다. IVD 수탁 제조 기업은 정밀의료에 대한 노력을 지원하기 위해 개인화 진단 장비 및 구성 요소의 개발 및 제조에 중요한 역할을합니다.

주요 시장 성장 촉진요인

기술 진보

맞춤형 의료에 대한 관심 증가

건강 관리 시장의 세계화 진전

주요 시장 과제

비용 압력

시장 세분화

주요 시장 동향

사용자 정의 및 유연성

부문별 인사이트

디바이스 유형별 인사이트

기술별 인사이트

지역별 인사이트

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 IVD 수탁 제조 시장 전망

제6장 북미의 IVD 수탁 제조 시장 전망

제7장 유럽의 IVD 수탁 제조 시장 전망

제8장 아시아 태평양의 IVD 수탁 제조 시장 전망

제9장 남미의 IVD 수탁 제조 시장 전망

제10장 중동 및 아프리카의 IVD 수탁 제조 시장 전망

제11장 시장 역학

제12장 시장 동향 및 발전

제13장 Porter's Five Forces 분석

제14장 경쟁 구도

제15장 전략적 제안

제16장 기업 소개 및 면책사항

LYJ
영문 목차

영문목차

Global IVD Contract Manufacturing Market was valued at USD 15.47 billion in 2023 and experience an impressive growth in the forecast period at a CAGR of 11.61% through 2029.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 15.47 Billion
Market Size 2029USD 29.79 Billion
CAGR 2024-202911.61%
Fastest Growing SegmentImmunoassay
Largest MarketNorth America

IVD (In Vitro Diagnostics) contract manufacturing refers to the outsourcing of manufacturing processes related to in vitro diagnostic products and services to specialized third-party manufacturers. In vitro diagnostics involve the analysis of biological samples such as blood, urine, tissue, and other bodily fluids outside the human body to diagnose diseases, monitor treatment responses, and assess overall health status. Contract manufacturers collaborate with IVD developers, diagnostic companies, and healthcare organizations to develop new diagnostic assays, test kits, instruments, and software solutions. This includes designing product specifications, formulating reagents, selecting components, and prototyping diagnostic devices. Contract manufacturers are responsible for producing IVD products in accordance with established quality standards, regulatory requirements, and industry best practices. This involves sourcing raw materials, manufacturing components, assembling finished products, conducting quality control testing, and packaging products for distribution. Contract manufacturers implement robust quality management systems and regulatory compliance processes to ensure the safety, efficacy, and reliability of IVD products. This includes adherence to international quality standards such as ISO 13485, FDA regulations, CE marking requirements, and other regional regulatory frameworks governing medical devices and diagnostics.

Ongoing advancements in diagnostic technologies, including molecular diagnostics, immunoassays, point-of-care testing, and automation, drive innovation and the development of new diagnostic products. IVD contract manufacturers leverage these advancements to develop and manufacture cutting-edge diagnostic devices and components. Healthcare providers and diagnostic companies increasingly outsource manufacturing processes to specialized contract manufacturers to streamline operations, reduce costs, and access specialized expertise. Outsourcing allows companies to focus on core competencies such as research, development, and marketing while leveraging the manufacturing capabilities of contract manufacturers. There is a growing emphasis on personalized medicine and precision diagnostics, which require customized diagnostic products tailored to individual patient needs. IVD contract manufacturers play a key role in developing and manufacturing personalized diagnostic devices and components to support precision medicine initiatives.

Key Market Drivers

Technological Advancements

Automation and robotics have revolutionized manufacturing processes in the IVD industry. Automated systems enable high-throughput production, improve efficiency, reduce human error, and ensure consistent product quality. Robotics are used for tasks such as sample handling, liquid dispensing, and assembly, leading to increased manufacturing speed and accuracy. Miniaturization and microfluidic technologies have enabled the development of compact and portable diagnostic devices for point-of-care testing. Microfluidic systems manipulate small volumes of fluids and enable rapid analysis of biological samples. These technologies offer benefits such as reduced sample and reagent consumption, faster analysis times, and improved sensitivity and specificity of diagnostic tests. Molecular diagnostics technologies, including polymerase chain reaction (PCR), nucleic acid amplification, next-generation sequencing (NGS), and microarray analysis, have transformed the detection and analysis of nucleic acids, proteins, and other biomarkers. Molecular diagnostics enable the identification of pathogens, genetic mutations, and disease biomarkers with high sensitivity and specificity, facilitating early disease detection, personalized treatment, and monitoring of treatment response. Immunodiagnostics technologies, such as enzyme-linked immunosorbent assays (ELISA), chemiluminescent immunoassays, and lateral flow assays, have advanced significantly in recent years. These technologies enable the detection and quantification of antibodies, antigens, and other immune markers in biological samples. Improvements in assay sensitivity, specificity, and multiplexing capabilities have expanded the applications of immunodiagnostics in infectious disease testing, autoimmune disease monitoring, cancer biomarker detection, and drug development.

Integration of data management systems, connectivity features, and cloud-based platforms enables seamless communication and data exchange between diagnostic instruments, laboratory information systems (LIS), electronic health records (EHR), and other healthcare IT systems. Data integration and connectivity facilitate real-time monitoring of diagnostic results, improve workflow efficiency, support remote diagnostics, and enable data-driven decision-making in healthcare settings. Advanced quality control and assurance technologies, such as process analytical technology (PAT), statistical process control (SPC), and automated inspection systems, ensure the consistency, reliability, and compliance of manufacturing processes and products. These technologies enable real-time monitoring of critical process parameters, early detection of deviations, and rapid corrective actions, minimizing the risk of product defects and regulatory non-compliance. Technological advancements in genomics, proteomics, and bioinformatics have facilitated the discovery and validation of biomarkers associated with disease risk, prognosis, and treatment response. Personalized medicine approaches leverage biomarker information to stratify patients, guide treatment decisions, and monitor disease progression. IVD contract manufacturers contribute to personalized medicine initiatives by developing and manufacturing companion diagnostics, pharmacogenomic tests, and other personalized diagnostic products. This factor will help in the development of the Global IVD Contract Manufacturing Market.

Increasing Focus on Personalized Medicine

Companion diagnostics are IVD tests that provide information about the patient's molecular or genetic profile to guide treatment decisions, such as selecting the most effective therapy or determining the optimal dosage. IVD contract manufacturers collaborate with pharmaceutical companies and diagnostic developers to develop and manufacture companion diagnostics, ensuring they meet regulatory requirements and perform reliably in clinical settings. Pharmacogenomics examines how an individual's genetic makeup influences their response to drugs. Pharmacogenomic tests help healthcare providers personalize medication selection, dosage, and treatment regimens to optimize therapeutic outcomes and minimize adverse reactions. IVD contract manufacturers produce pharmacogenomic testing kits and platforms, enabling healthcare providers to integrate pharmacogenomic testing into routine clinical practice. Biomarkers are measurable indicators of biological processes or disease states that can be used for diagnosis, prognosis, and treatment monitoring. Technological advancements in genomics, proteomics, and bioinformatics enable the discovery and validation of biomarkers associated with specific diseases, treatment responses, and patient outcomes. IVD contract manufacturers contribute to biomarker discovery efforts by developing and validating assays and testing platforms for detecting and quantifying biomarkers in clinical samples.

Personalized medicine often requires customized diagnostic assays tailored to the unique characteristics of individual patients or disease subtypes. IVD contract manufacturers specialize in developing and manufacturing customized assays and testing platforms, offering flexibility and scalability to meet the diverse needs of personalized medicine applications. Customized assays enable healthcare providers to profile patient-specific biomarkers, stratify patient populations, and tailor treatment strategies accordingly. Personalized medicine relies on integrated data management systems, electronic health records (EHR), and decision support tools to aggregate, analyze, and interpret patient-specific data, including genetic, molecular, clinical, and lifestyle information. IVD contract manufacturers develop connectivity features and data integration solutions that enable seamless communication between diagnostic instruments, healthcare IT systems, and clinical decision support platforms, facilitating data-driven personalized medicine approaches. This factor will pace up the demand of the Global IVD Contract Manufacturing Market.

Rising Globalization of Healthcare Markets

As healthcare markets expand globally, there is an increasing demand for diagnostic products and services, including IVD tests and assays. The globalization of healthcare markets opens up new opportunities for IVD manufacturers to penetrate emerging markets and meet the growing demand for diagnostic testing. Emerging economies, particularly in Asia, Latin America, and Africa, are witnessing rapid economic growth and urbanization, leading to improvements in healthcare infrastructure and increased access to medical services. As healthcare standards rise in these regions, there is a corresponding increase in demand for diagnostic testing to support disease diagnosis, monitoring, and treatment.

Many regions are experiencing shifts in disease burden, with a growing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer. Additionally, infectious diseases and emerging pathogens remain significant healthcare challenges globally. The demand for IVD tests and assays to diagnose and manage these diseases drives the need for contract manufacturing services to produce diagnostic products efficiently and cost-effectively. The globalization of healthcare markets has led to efforts to standardize regulatory requirements and harmonize regulatory frameworks across different regions. Regulatory harmonization facilitates market access for IVD manufacturers by streamlining the regulatory approval process and reducing barriers to entry in international markets.

The globalization of healthcare markets allows healthcare providers and diagnostic laboratories in emerging economies to access advanced diagnostic technologies and expertise from established markets. IVD contract manufacturers play a vital role in transferring technology, knowledge, and expertise to emerging markets, enabling healthcare providers to offer state-of-the-art diagnostic services to their patients. Globalization encourages partnerships and collaborations between IVD manufacturers, healthcare providers, government agencies, and non-profit organizations to address healthcare challenges and improve access to diagnostic testing worldwide. IVD contract manufacturers often form strategic alliances with local partners to establish manufacturing facilities, distribution networks, and technical support services in emerging markets. The increasing adoption of telemedicine and remote healthcare solutions enables patients in remote and underserved areas to access diagnostic services and medical consultations remotely. IVD contract manufacturers develop and produce point-of-care diagnostic devices and remote monitoring solutions that support telemedicine initiatives and improve healthcare access in remote and rural communities. This factor will accelerate the demand of the Global IVD Contract Manufacturing Market.

Key Market Challenges

Cost Pressures

The IVD contract manufacturing market is highly competitive, with numerous players vying for market share. Intense competition exerts downward pressure on prices, as manufacturers may offer discounts or lower margins to secure contracts with clients. IVD contract manufacturers face increasing operating costs, including expenses related to labor, raw materials, equipment, facilities, and regulatory compliance. Rising costs squeeze profit margins and make it challenging to maintain competitiveness while ensuring quality and compliance. Keeping pace with technological advancements and industry standards requires significant investments in research, development, and technology upgrades. Contract manufacturers must invest in state-of-the-art equipment, automation, and quality control measures to remain competitive, adding to their operational costs. Adhering to stringent regulatory requirements and quality standards imposed by health authorities worldwide incurs additional costs for IVD contract manufacturers. Compliance with regulations such as ISO 13485, FDA Quality System Regulation (QSR), and EU In Vitro Diagnostic Regulation (IVDR) requires investment in personnel, training, documentation, and quality management systems.

Market Fragmentation

The IVD contract manufacturing market consists of numerous players, including large multinational corporations, mid-sized companies, and smaller niche players. The presence of numerous competitors leads to fragmentation and diversity in the market landscape. IVD contract manufacturers produce a wide range of diagnostic products and services, including reagents, assay kits, instruments, and software solutions, targeting various disease areas, analytical techniques, and customer segments. The diversity of product offerings contributes to market fragmentation as companies specialize in different niches and segments of the market. The IVD market exhibits regional variations in terms of regulatory requirements, healthcare infrastructure, disease prevalence, and market dynamics. Market fragmentation occurs as companies tailor their products and services to meet the specific needs and preferences of customers in different geographic regions. IVD contract manufacturers often possess specialized expertise in particular disease areas, analytical techniques, or technology platforms. Companies differentiate themselves by offering unique capabilities, proprietary technologies, and value-added services, leading to fragmentation in the market.

Key Market Trends

Customization and Flexibility

IVD manufacturers serve a diverse customer base, including healthcare providers, diagnostic companies, research institutions, and pharmaceutical companies. Each customer has unique requirements for diagnostic products, assays, and testing platforms tailored to their specific applications, disease areas, patient populations, and regulatory environments. The shift towards personalized medicine and precision diagnostics drives the demand for customized diagnostic solutions that address individual patient characteristics, genetic variations, and treatment responses. IVD contract manufacturers play a crucial role in developing personalized diagnostic assays, companion diagnostics, and pharmacogenomic tests that enable tailored treatment strategies and improve patient outcomes. Technological advancements in genomics, proteomics, microfluidics, automation, and data analytics enable the development of innovative diagnostic platforms and assays with enhanced sensitivity, specificity, and multiplexing capabilities. IVD contract manufacturers leverage these technologies to develop customizable and adaptable solutions that meet evolving customer needs and market trends. IVD contract manufacturers design modular and scalable diagnostic platforms that allow customers to customize assay panels, reagent combinations, and instrument configurations based on their specific testing requirements. Modular platforms enable flexibility in assay design, workflow optimization, and throughput scalability, accommodating diverse laboratory settings and testing volumes.

Segmental Insights

Device Type Insights

The IVD Consumables segment is projected to experience rapid growth in the Global IVD Contract Manufacturing Market during the forecast period. There is a growing demand for diagnostic testing worldwide, driven by factors such as the aging population, the rising prevalence of chronic and infectious diseases, and increased awareness about early disease detection and prevention. IVD consumables, including reagents, assays, and test kits, are essential components of diagnostic tests, driving demand in this segment. Point-of-care testing (POCT) is gaining popularity due to its convenience, rapid results, and potential to improve patient outcomes. POCT devices require consumables such as test strips, cartridges, and reagents for performing tests at the point of care. The expansion of POCT technologies fuels the demand for consumables in the IVD market. Healthcare providers and diagnostic companies increasingly outsource manufacturing processes to specialized contract manufacturers to streamline operations, reduce costs, and access specialized expertise. Contract manufacturers offer expertise in design, development, manufacturing, and quality control of IVD consumables, driving growth in this segment.

Technology Insights

The Coagulation & Hemostasis segment is projected to experience rapid growth in the Global IVD Contract Manufacturing Market during the forecast period. There has been a rise in the prevalence of hemostasis disorders such as thrombosis, hemophilia, and von Willebrand disease globally. These conditions necessitate frequent monitoring of coagulation and hemostasis parameters, driving the demand for diagnostic tests and assays in this segment. The aging population is more prone to coagulation disorders and hemostasis-related conditions due to age-related changes in blood composition and increased risk of chronic diseases. As the global population continues to age, there is a growing need for diagnostic testing and monitoring of coagulation parameters, fueling demand in the Coagulation & Hemostasis segment. Technological advancements in coagulation testing methods, including automated analyzers, point-of-care testing devices, and molecular diagnostics, have improved the accuracy, efficiency, and speed of testing. These advancements drive the adoption of coagulation and hemostasis assays and contribute to market growth.

Regional Insights

North America emerged as the dominant region in the Global IVD Contract Manufacturing Market in 2023. North America boasts a well-developed healthcare infrastructure, including advanced medical facilities, research institutions, and regulatory frameworks. This infrastructure supports the demand for IVD products and services, driving the growth of contract manufacturing in the region. The region is a hub for technological innovation and research in the healthcare and life sciences industries. North American companies and research institutions are at the forefront of developing cutting-edge diagnostic technologies, driving demand for contract manufacturing services to bring these innovations to market. The United States and Canada have robust regulatory frameworks governing the manufacturing and distribution of medical devices, including IVD products. While stringent, these regulations provide clarity and consistency for manufacturers, fostering a conducive environment for contract manufacturing operations.

Key Market Players

Thermo Fisher Scientific Inc.

Siemens Healthineers AG

Danaher Corporation

F. Hoffmann-La Roche Ltd.

Ortho Clinical Diagnostics

Abbott Laboratories

Bio-Rad Laboratories, Inc.

Sysmex Corporation

Quidel Corporation

BioMerieux SA

Report Scope:

In this report, the Global IVD Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

IVD Contract Manufacturing Market, By Device Type:

IVD Contract Manufacturing Market, By Technology:

IVD Contract Manufacturing Market, By Service Type:

IVD Contract Manufacturing Market, By Region:

United States

Canada

Mexico

Germany

United Kingdom

France

Italy

Spain

China

Japan

India

Australia

South Korea

Brazil

Argentina

Colombia

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global IVD Contract Manufacturing Market.

Available Customizations:

Global IVD Contract Manufacturing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global IVD Contract Manufacturing Market Outlook

6. North America IVD Contract Manufacturing Market Outlook

7. Europe IVD Contract Manufacturing Market Outlook

8. Asia-Pacific IVD Contract Manufacturing Market Outlook

9. South America IVD Contract Manufacturing Market Outlook

10. Middle East and Africa IVD Contract Manufacturing Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Porter's Five Forces Analysis

14. Competitive Landscape

15. Strategic Recommendations

16. About Us & Disclaimer

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기